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52 Poster Session Ipost HSCT. CD41 recovery appears to occur at a pace comparable
to that of matched-sibling HSCT recipients. This 2 step procedure
promotes the establishment of donor-recipient tolerance by in vivo
CTX exposure, but avoids any effects of G-CSF on donor lympho-
cytes, allows delivery of a precise dose of T cells to all patients, and
eliminates CTX exposure of the hematopoietic precursors. Patients
who lack matched-sibling donors can be successfully transplanted
on this protocol with little significant GVHD. Infection and relapse
remain problems, but likely can be reduced through transplantation
of patients earlier in their disease course.
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Non-myeloablative 2.0 3.04 0.01 0 NED @ d 1 19136
OptiMatch – OPTIMIZED SELECTION OF ALLELE MATCHED UNRE-
LATED DONORS FROM A LARGE DATABASE
Bochtler,W., Eberhard, H.-P., Beth,M.,Mueller, C.R. ZKRDZentrales
Knochenmarkspender-Register Deutschland, Ulm, Germany.
The standard for unrelated donor selection is defined by allele
level matching for, at least, HLA-A, -B and -DRB1 with a strong
tendency to also include HLA-C and/or -DQB1. Even for patients
where such donors will likely exist, the search is hampered by the
high prevalence of donors where some of these loci are only typed
at intermediate or low resolution, by serology or not at all. A large
registry like ZKRDwith over 3million donors can have lists of hun-
dreds or even thousands of similar donor candidates for a substantial
fraction of the patients making an efficient search strategy difficult.
ZKRD’s new OptiMatch system addresses the issues raised by
a three layer concept:
(1) The DNA-based search engine uses serology-to-DNA map-
ping for the identification of donor candidates. The degree of
matching can be determined using combinatorial or biostatistical
methods. Moreover, the probability of allele level matching of
each candidate can not only be determined for each locus based
on the allele frequencies of the German population but also much
more reliably based on allele resolution haplotype frequencies for
HLA-A-B-DRB1, HLA-C-B and HLA-DRB1-DQB1.
(2) The web-based front end allows extensive configuration of the
way match lists are filtered and sorted, for example: Primary match-
ing can be based on the probability of matching 6/6, 8/8 (including
C or DQB1) or 10/10 (including both) alleles, and then the proba-
bility of 1 or, finally, 2 allele mismatches. Filters can be applied for
gender, CMV status and loci already typed.
(3) The sophisticated security architecture is based on strong au-
thentication of users and encrypted data transmission.The new OptiMatch search engine has been in use since late
2006. Its ability to identify some very likely matching donors among
myriads of multiple allele codes gives a stunning power to profes-
sional search coordinators. Even inmost difficult cases it is apparent
upfront which degree of matching can possibly be sought for, which
donors should be considered first and which time frame and cost
volume should be expected.
During its ongoing test phase, the web-based front end is only
available in ZKRD’s intranet but will be released to outside beta tes-
ters before the end of 2007.137
POTENTIAL ROLE OF A MISMATCHED HLA-SPECIFIC CTL CLONE DEVEL-
OPED PRE-TRANSPLANT IN GRAFT REJECTION FOLLOWING CORD
BLOOD TRANSPLANTATION
Murata, M., Narimatsu, H., Terakura, S., Sugimoto, K., Naoe, T. Na-
goya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Graft rejection is a significant complication in cord blood trans-
plantation (CBT), but little is known about the mechanism of rejec-
tion. In the present study, to investigate the potential role of T
lymphocytes in graft rejection, we isolated a CD81 cytotoxicT lym-
phocyte (CTL) clone from a patient with graft rejection after CBT
from an HLA-mismatched unrelated donor. Peripheral blood
mononuclear cells (PBMCs) obtained from the patient just after
the onset of graft rejection were cultured in interleukin-2 contain-
ing media without stimulator cells, and two CTL clones were iso-
lated by limiting dilution. One clone, designated N19D8, lysed
Epstein Barr virus transformed lymphoblastoid cells (B-LCL)
from the donor, but failed to lyse B-LCL from the patient, suggest-
ing that this CTL clone has the possibility of involvement in the im-
munological graft rejection. Fluorescent in situ hybridization for sex
chromosome indicated that N19D8 clone was originated from the
patient. In a cytotoxicity assay, N19D8 CTL lysed all of four B-
LCL lines from unrelated individuals that shared HLA-B*1501
but failed to lyse B-LCL from eight unrelated individuals without
B*1501. These data suggested that N19D8 CTL recognized
HLA-B*1501 molecule as an alloantigen, which was expressed in
donor cells but not in patient cells. The patient B-LCL transfected
withHLA-B*1501 cDNA alone were clearly lysed by N19D8 CTL,
and COS cells transfected with HLA-B*1501 cDNA alone stimu-
lated interferon-g production ofN19D8CTL.Thus, we concluded
that the N19D8 CTL clone recognizes mismatched HLA-B*1501
molecule as an alloantigen. We next determine whether the
N19D8 clone was developed prior to transplantation. The micro-
chimerism analyses specific for HLA-B*1501 gene and PCR assays
specific for the N19D8 CTL clone’s uniquely rearranged T cell re-
ceptor Vb17 chain gene on DNA from pre-transplant PBMCs re-
vealed that the patient was exposed to HLA-B*1501 prior to CBT
andN19D8 clone was developed in the patient’s blood before trans-
plantation. Interestingly, her daughter has HLA-B*1501 in an in-
herited paternal allele, suggesting that the patient might be
exposed to HLA-B*1501 during her pregnancy. In conclusion, the
present study demonstrated the potential role of pre-transplant
CTL in graft rejection following CBT. Further studies focusing
on mismatched HLA-specific CTLs should help establish the opti-
mal strategy to overcome graft rejection in CBT.138
CHARACTERISTICS OF 11 CASES OF PRE-ENGRAFTMENT LYMPHOCYTO-
SIS AFTER REDUCED-INTENSITY CORD BLOOD TRANSPLANTATION
Yamamoto, H., Wake, A., Ishiwata, K., Tuji, M., Takagi, S., Kato, D.,
Matsuhashi, Y., Sea, S., Matsuno, N., Uchida, N., Masuoka, K.,
Yoneyama, A., Taniguchi, S. Toranomon Hospital, Minato-ku Torano-
mon, Tokyo, Japan.
Wehave reported higher incidence of immune-mediated compli-
cations, such as pre-engraftment immune reaction (PIR), character-
ized by high-grade fever, skin eruption, diarrhea, jaundice and body
weight gain developing before engraftment or hemophagocytic
